lncRNA TPRG1-AS1 Screened the Onset of Acute Coronary Syndromes and Predicted Severity and the Occurrence of MACE During Patients’ Hospitalization

References

• Ahmadi A, Argulian E, Leipsic J, Newby DE, Narula J. From subclinical atherosclerosis to plaque progression and acute coronary events: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(12):1608–1617. doi:10.1016/j.jacc.2019.08.012
   PubMed Web of Science ®Google Scholar
• Smith JN, Negrelli JM, Manek MB, Hawes EM, Viera AJ. Diagnosis and management of acute coronary syndrome: an evidence-based update. J Am Board Fam Med. 2015;28(2):283–293. doi:10.3122/jabfm.2015.02.140189
   PubMed Web of Science ®Google Scholar
• Boyd B, Zamora CA, Castillo M. Managing adverse reactions to contrast agents. Magn Reson Imaging Clin N Am. 2017;25(4):737–742. doi:10.1016/j.mric.2017.06.008
   PubMed Web of Science ®Google Scholar
• Marraccini P, Bianchi M, Fommei E, et al. Contrast medium nephrotoxicity after renal artery and coronary angioplasty. Acta radiologica. 2010;51(4):462–466. doi:10.3109/02841851003629045
   PubMed Web of Science ®Google Scholar
• Wang L, Jin Y. Noncoding RNAs as biomarkers for acute coronary syndrome. Biomed Res Int. 2020;2020:3298696. doi:10.1155/2020/3298696
   PubMed Web of Science ®Google Scholar
• Li L, Wang L, Li H, et al. Characterization of LncRNA expression profile and identification of novel LncRNA biomarkers to diagnose coronary artery disease. Atherosclerosis. 2018;275:359–367. doi:10.1016/j.atherosclerosis.2018.06.866
   PubMed Web of Science ®Google Scholar
• Ren X, Zhu H, Deng K, et al. Long noncoding RNA TPRG1-AS1 suppresses migration of vascular smooth muscle cells and attenuates atherogenesis via interacting with MYH9 protein. Arterioscler Thromb Vasc Biol. 2022;42(11):1378–1397. doi:10.1161/ATVBAHA.122.318158
   PubMed Web of Science ®Google Scholar
• Choi JH, Kwon SM, Moon SU, et al. TPRG1-AS1 induces RBM24 expression and inhibits liver cancer progression by sponging miR-4691-5p and miR-3659. Liver Int. 2021;41(11):2788–2800. doi:10.1111/liv.15026
   PubMed Web of Science ®Google Scholar
• He J, Dong C, Zhang H, Jiang Y, Liu T, Man X. The oncogenic role of TFAP2A in bladder urothelial carcinoma via a novel long noncoding RNA TPRG1-AS1/DNMT3A/CRTAC1 axis. Cell Signal. 2023;102:110527. doi:10.1016/j.cellsig.2022.110527
   PubMed Web of Science ®Google Scholar
• Li Z, Qiu X, He Q, Fu X, Ji F, Tian X. CCND1-associated ceRNA network reveal the critical pathway of TPRG1-AS1-hsa-miR-363-3p-MYO1B as a prognostic marker for head and neck squamous cell carcinoma. Sci Rep. 2023;13(1):11831. doi:10.1038/s41598-023-38847-7
   PubMedGoogle Scholar
• Kimura K, Kimura T, Ishihara M, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83(5):1085–1196. doi:10.1253/circj.CJ-19-0133
   PubMed Web of Science ®Google Scholar
• Chhabra ST, Kaur T, Masson S, et al. Early onset ACS: an age based clinico-epidemiologic and angiographic comparison. Atherosclerosis. 2018;279:45–51. doi:10.1016/j.atherosclerosis.2018.10.017
   PubMed Web of Science ®Google Scholar
• Kringeland E, Tell GS, Midtbø H, Igland J, Haugsgjerd TR, Gerdts E. Stage 1 hypertension, sex, and acute coronary syndromes during midlife: the Hordaland Health Study. Eur J Prev Cardiol. 2022;29(1):147–154. doi:10.1093/eurjpc/zwab068
   PubMed Web of Science ®Google Scholar
• Manfrini O, Cenko E, Bugiardini R. Gender differences in residual risk factors for major adverse cardiovascular events following ACS and how to bridge the gap. Curr Atheroscler Rep. 2020;22(11):65. doi:10.1007/s11883-020-00882-4
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Natsuaki M, Morimoto T, et al. Coronary artery disease without standard cardiovascular risk factors. Am J Cardiol. 2022;164:34–43. doi:10.1016/j.amjcard.2021.10.032
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang Y, Liu J, et al. Role of lipoprotein(a) in predicting the severity of new on-set coronary artery disease in type 2 diabetics: a Gensini score evaluation. Diab Vasc Dis Res. 2015;12(4):258–264. doi:10.1177/1479164115579004
   PubMed Web of Science ®Google Scholar
• Rampidis GP, Benetos G, Benz DC, Giannopoulos AA, Buechel RR. A guide for Gensini score calculation. Atherosclerosis. 2019;287:181–183. doi:10.1016/j.atherosclerosis.2019.05.012
   PubMed Web of Science ®Google Scholar
• Tanaka T, Miki K, Akahori H, et al. Comparison of coronary atherosclerotic disease burden between ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: non-culprit Gensini score and non-culprit SYNTAX score. Clin Cardiol. 2021;44(2):238–243. doi:10.1002/clc.23534
   PubMed Web of Science ®Google Scholar
• Doganer YC, Aydogan U, Aydogdu A, et al. Relationship of cystatin C with coronary artery disease and its severity. Coron Artery Dis. 2013;24(2):119–126. doi:10.1097/MCA.0b013e32835b6761
   PubMed Web of Science ®Google Scholar
• van der Laan SW, Fall T, Soumaré A, et al. Cystatin C and cardiovascular disease: a Mendelian randomization study. J Am Coll Cardiol. 2016;68(9):934–945. doi:10.1016/j.jacc.2016.05.092
   PubMed Web of Science ®Google Scholar
• Wallentin L, Eriksson N, Olszowka M, et al. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: a retrospective study. PLoS Med. 2021;18(1):e1003513. doi:10.1371/journal.pmed.1003513
   PubMed Web of Science ®Google Scholar
• Wang GN, Sun K, Hu DL, Wu HH, Wang XZ, Zhang JS. Serum cystatin C levels are associated with coronary artery disease and its severity. Clin Biochem. 2014;47(16–17):176–181. doi:10.1016/j.clinbiochem.2014.07.013
   PubMed Web of Science ®Google Scholar
• Almeida R, Mariano L, Gavina C, et al. The value of NT-proBNP in early risk stratification of acute coronary syndromes. Port J Cardiol. 2006;25(1):71–75.
   Google Scholar
• Fan J, Ma J, Xia N, Sun L, Li B, Liu H. Clinical value of combined detection of CK-MB, MYO, cTnI and plasma NT-proBNP in diagnosis of acute myocardial infarction. Clin Lab. 2017;63(3):427–433. doi:10.7754/Clin.Lab.2016.160533
   PubMed Web of Science ®Google Scholar
• Hamaya R, Yonetsu T, Kanaji Y, et al. Interrelationship in the prognostic efficacy of regional coronary flow reserve, fractional flow reserve, high-sensitivity cardiac troponin-I and NT-proBNP in patients with stable coronary artery disease. Heart Vessels. 2019;34(3):410–418. doi:10.1007/s00380-018-1260-z
   PubMed Web of Science ®Google Scholar
• Mal K, Kumar R, Mansoor F, et al. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis. Cureus. 2020;12(12):e12246. doi:10.7759/cureus.12246
   PubMed Web of Science ®Google Scholar
• Simonetto M, Murthy SB. Major adverse cardiovascular events after intracerebral hemorrhage-it’s all about location, location, location. JAMA Netw Open. 2023;6(4):e235783. doi:10.1001/jamanetworkopen.2023.5783
   PubMed Web of Science ®Google Scholar
• Yang K, Liu W. Triglyceride and glucose index and sex differences in relation to major adverse cardiovascular events in hypertensive patients without diabetes. Front Endocrinol (Lausanne). 2021;12:761397. doi:10.3389/fendo.2021.761397
   PubMed Web of Science ®Google Scholar
• Nopp S, van der Bent ML, Kraemmer D, et al. Circulatory miR-411-5p as a novel prognostic biomarker for major adverse cardiovascular events in patients with atrial fibrillation. Int J Mol Sci. 2023;24(4):3861. doi:10.3390/ijms24043861
   PubMed Web of Science ®Google Scholar
• Tang QJ, Lei HP, Wu H, et al. Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy. Acta Pharmacol Sin. 2019;40(2):208–215. doi:10.1038/s41401-018-0041-7
   PubMed Web of Science ®Google Scholar